This article is more than 5 years old. Information may no longer be current.

Micropulse treatment may be better than anti-VEGF in treating central serous chorioretinopathy

Eye. 2011; doi:10.1038/eye.2011.282.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MicroPulse laser therapy may be superior to intravitreal bevacizumab injections in treating patients with central serous chorioretinopathy, according to a study.

The comparative, prospective study evaluated 16 eyes treated with subthreshold diode laser MicroPulse (Iridex), 10 eyes treated with 1.25 mg Avastin (bevacizumab, Genentech) and 26 controls. At 10 months, persistent retinal pigment epithelium leakage was observed in 12.5% of MicroPulse eyes, 60% of bevacizumab eyes and 92% of control eyes.

Mean best corrected visual acuity improved more than six letters in the MicroPulse group, compared with a decrease of one letter and two letters in the bevacizumab group and control group, respectively.

In the MicroPulse group, mean central macular thickness decreased by 94 µm. The decrease was 38 µm in the bevacizumab group, and there was no change in central macular thickness in the control group.

"Because of the absence of laser-induced retinal damage discernable at any time postoperatively, subvisible MicroPulse photocoagulation, with no focal burn end point (or its consequences), represents an elegant medical approach and a true clinical alternative," Frank Koch, MD, co-author of the study, said in a press release from Iridex announcing the results.